FGFR3 and small cell lung carcinoma: After only 7 weeks of therapy the patient developed metastatic pleural effusion, in which we detected transformation to SCLC that retained the EGFR- and FGFR3-mutations and partly responded to the following combination of carboplatin-etoposide and erlotinib-continuation.